Research Analysts Offer Predictions for BCRX FY2025 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for BioCryst Pharmaceuticals in a research report issued on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse expects that the biotechnology company will earn ($0.27) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $20.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share.

BCRX has been the subject of a number of other reports. Evercore ISI upped their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. JMP Securities restated a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Royal Bank of Canada reiterated an “outperform” rating and issued a $11.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, April 11th. Wedbush began coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $16.13.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock opened at $8.71 on Thursday. The firm has a fifty day moving average price of $7.68 and a 200-day moving average price of $7.79. BioCryst Pharmaceuticals has a 1 year low of $4.41 and a 1 year high of $9.50. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -14.28 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. The company’s revenue was up 40.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.28 EPS.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds have recently modified their holdings of BCRX. Vanguard Group Inc. boosted its stake in shares of BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock worth $164,616,000 after acquiring an additional 1,583,826 shares in the last quarter. Principal Financial Group Inc. lifted its position in BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after buying an additional 375,890 shares in the last quarter. Teacher Retirement System of Texas boosted its position in shares of BioCryst Pharmaceuticals by 25.1% during the 4th quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company’s stock valued at $438,000 after acquiring an additional 11,711 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in BioCryst Pharmaceuticals by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock valued at $14,890,000 after purchasing an additional 91,998 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in BioCryst Pharmaceuticals in the fourth quarter worth approximately $80,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.